April 6, 1999

Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm, 1061 Rockville, MD 20852

5673 '99 APR 13 A11:06

Regarding Docket No. 98N-1265

Dear Sirs:

I just received my three-month supply of Tri-Estrogen from Madison Pharmacy Associates and was informed of this legislation that would greatly restrict my ability to get more medication. I am writing to ask you not to pass this legislation.

Four years ago, at age 41, I had a complete hysterectomy including removal of the ovaries due to both ovarian and uterine cysts. It is therefore necessary that I take Estrogen replacement. I tried Premarin for the first few months, but it caused swelling and extreme tenderness in my breasts. Besides this, Premarin is known to increase the risk of breast cancer, which I already have risk factors for. So, I asked my doctor if there was something safer. She showed me research about Estrogen that is extracted from plants that actually lowers the risk of breast cancer, and then suggested I try Tri-Estrogen because it is 80% plant-based, plus 10% of the type of Estrogen in Premarin and 10% of the third type of Estrogen our ovaries normally produce. I have had good success with this product: only minor breast tenderness at times and I feel much safer taking it due to the lowered (rather than increased) cancer risk.

This excellent product is a compounded prescription and is not available in Arizona, since local pharmacies and commercial manufacturers do not carry it. It is easily available currently by mail order from Wisconsin, but if your legislation passes, they will not be able to ship to me. I do not want to go back to taking Premarin. It may be OK for some women, but it is not for me.

Please do not restrict in any way the prescriptions that can be shipped out of state by any pharmacy. Please continue to allow my doctor and me to decide which hormone replacement is best for my case. I ask again that Docket No. 98N-1265 on the Federal/State Memorandum of Understanding on Interstate Distribution of Compounded Drug Products NOT be approved.

Sincerely,

Cheryl A. Black Cheryl A. Black P.O. Box 8987

Catalina, AZ 85738-0987

981-1265

C 1071







Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane, rm 1061
Rockville, MD 20852

Docket No: 98N-1265

20857/0001 30

Intilludation illustration illustration illustration